News Sentiment

JSPR sentiment intelligence

Jasper Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.58 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+35.3% over one week, +26.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 35.3% Price confirming higher
Trend fit Trend inactive 26.6% over four weeks
Fair value -94.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 40
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 9
TradingKey 7
Stock Titan 3
GlobeNewswire 3
MT Newswires 3
simplywall.st 3
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 16
Deals and strategy 6
Analyst action 6
Regulatory and legal 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Titan Direct company coverage

Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake

Entities affiliated with Millennium Management have reported a 1.7% equity stake in Jasper Therapeutics (NASDAQ: JSPR), beneficially owning up to 486,933 shares of its voting common stock as of June 30, 2026. This disclosure was made via a Schedule 13G/A SEC filing, indicating pa

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 22:10
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

This article provides financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically focusing on its price-to-earnings forward metric. The content includes a brief overview of the company's financial data as presented on TradingView. It appears to be a stub or

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 08:40
Source
TradingView
AD HOC NEWS Direct company coverage

Jasper Therapeutics stock holds the focus. Company profile stays central.

Jasper Therapeutics (JSPR) is a clinical-stage biotechnology company listed on Nasdaq, with its stock performance currently driven by its company profile and development pipeline. The lead program, briquilimab, focuses on antibody-based therapies for immune-mediated diseases, par

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:42
Source
AD HOC NEWS
TradingView Direct company coverage

Enterprise value to EBIT forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

The article discusses the enterprise value to EBIT forward for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) as presented on TradingView. It appears to be a financial data page rather than a detailed analysis. The content primarily lists navigation and platform features, indicating a

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 13:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

This article provides the "Price to sales forward" metric for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) on TradingView. It indicates that the market is closed with no trades and lists various sections typical of a financial data platform. The content is mostly boilerplate from a f

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 08:39
Source
TradingView
Finviz Direct company coverage

JSPR - Jasper Therapeutics Inc Options

This article provides a detailed financial overview of Jasper Therapeutics Inc (JSPR), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $0.4283, experiencing a 5.76% decre

Tone
Negative 18/100
Event
Analyst action
Published
03 Jul 2026 15:38
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR

This page provides financial data, specifically the "Price to sales forward" metric, for Jasper Therapeutics, Inc. (NASDAQ: JSPR). The content appears to be a financial data presentation or a module within a larger financial platform like TradingView, with information about the s

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 07:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Jasper Therapeutics, Inc. – NASDAQ:JSPR

This article displays the "Enterprise value to revenue forward" metric for Jasper Therapeutics, Inc. (NASDAQ: JSPR) on TradingView. It shows the company's financial data, though the specific value for the metric is not provided in the snippet. The page indicates trading activity

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 13:40
Source
TradingView
TradingView Direct company coverage

Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings

This article provides a listing of Jasper Therapeutics, Inc.'s SEC filings and other key documents, including earnings reports, corporate presentations, and study results for its briquilimab drug candidate. The documents reveal strong clinical progress in treatments for condition

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 09:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

This article displays financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically its enterprise value to revenue forward. The content appears to be a stub or a section within a larger financial data platform like TradingView, with a focus on providing speci

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 08:39
Source
TradingView
Sahm Direct company coverage

Insider Traders Lose US$287k As Jasper Therapeutics Drops

Insiders at Jasper Therapeutics (NASDAQ:JSPR) who bought US$347.5k worth of stock at an average price of US$2.43 have seen their investment drop significantly to US$60.0k after a 14% decrease in the stock price. Despite these recent losses, the fact that insiders purchased shares

Tone
Negative 33/100
Event
Market update
Published
01 Jul 2026 04:09
Source
Sahm
The National Law Review Direct company coverage

JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ:JSPR) for alleged federal securities law violations. The lawsuit claims that Jasper made materially false and misleading statements regarding its manufacturing contro

Tone
Negative 19/100
Event
Regulatory and legal
Published
29 Jun 2026 14:39
Source
The National Law Review
TradingView Direct company coverage

Price to earnings forward of Jasper Therapeutics, Inc. – BOATS:JSPRW

This article provides the "price to earnings forward" value for Jasper Therapeutics, Inc. (JSPRW). It focuses solely on this financial metric without offering additional analysis or context. The content is presented within the framework of financial data provided by TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:40
Source
TradingView
AD HOC NEWS Direct company coverage

Jasper Therapeutics Stock - Analyst consensus and weekly review

This article provides an analyst consensus and weekly review for Jasper Therapeutics (JSPR), a speculative small-cap biotech. It highlights the company's "Buy" rating profile from analysts, despite its early-stage pipeline and limited revenue, focusing on future clinical mileston

Tone
Positive 66/100
Event
Analyst action
Published
19 Jun 2026 23:01
Source
AD HOC NEWS
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis

This article from TradingKey analyzes the financial health of Jasper Therapeutics Inc (JSPRW) by examining its profitability and balance sheet. However, the report notes that relevant financial data for key metrics such as cash and cash equivalents, total assets, total liabilitie

Tone
Neutral 50/100
Event
Balance sheet
Published
19 Jun 2026 11:40
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jasper Therapeutics Inc (JSPR), including analyst ratings, target prices, and EPS expectations. Based on 8 analysts, the stock has a "Buy" rating with a target price of $10.50, representing a significant upside. The company's previou

Tone
Positive 71/100
Event
Earnings
Published
19 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPR) Institutional Confidence

This article provides details on the institutional confidence for Jasper Therapeutics Inc (JSPR), including top institutional shareholders and changes in their holdings. Key holders like Velan Capital, Morgan Stanley, and Millennium Management are listed with their share counts a

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Jasper Therapeutics Inc (JSPR), focusing on key financial metrics like P/E, P/B, P/S, and P/CF ratios. The report indicates that relevant data for these metrics have not yet been disclosed by the company. It also includes current sto

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 01:40
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Jasper Therapeutics Inc's (JSPRW) dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no records of stock split events. The current stock price

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPRW) Institutional Confidence

This article provides details on the institutional confidence score for Jasper Therapeutics Inc (JSPRW), showing a previous score of 0.00 with no change. It lists several institutional shareholders and their shareholdings, including changes in their positions. The primary focus i

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:11
Source
TradingKey
TradingKey Direct company coverage

Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Jasper Therapeutics Inc's (JSPR) dividend and stock split history. It notes that the company has not distributed dividends in the past five years and details a 10-to-1 merger-related stock split that occurred on January 2, 2024. The stock info

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 08:10
Source
TradingKey
Stock Titan Direct company coverage

Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes

Jasper Therapeutics (JSPR) will hold its 2026 annual stockholder meeting virtually on July 31, 2026. Key proposals include the election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 20:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice

Jasper Therapeutics (JSPR) has received a Nasdaq notice for falling below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 days, until November 30, 2026, to regain compliance, with its stock continuing to trade without immediate impact. Failure to

Tone
Negative 15/100
Event
Market update
Published
10 Jun 2026 15:56
Source
The Globe and Mail
GlobeNewswire Direct company coverage

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics, a clinical-stage biotechnology company, has announced that its Board of Directors is initiating a comprehensive review of strategic alternatives to maximize shareholder value. These alternatives include potential asset sales, licensing, collaborations, a comp

Tone
Negative 38/100
Event
Market update
Published
10 Jun 2026 05:11
Source
GlobeNewswire
Benzinga Direct company coverage

Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate

This "Deal Dispatch" article covers recent M&A activities and company news, including Jasper Therapeutics exploring strategic alternatives, private equity firm New Mountain Capital acquiring Asset Living for over $2 billion, and Robinhood's completion of its $180 million acquisit

Tone
Neutral 50/100
Event
Deals and strategy
Published
05 Jun 2026 17:09
Source
Benzinga
Minichart Direct company coverage

Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1

Jasper Therapeutics (Nasdaq: JSPR) has launched a strategic review to explore options such as asset sale/licensing, collaborations, company sale, mergers, or an orderly wind-down, aiming to maximize shareholder value. The company will also implement cost-saving measures and conti

Tone
Negative 39/100
Event
Deals and strategy
Published
01 Jun 2026 15:47
Source
Minichart